LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

Search

Editas Medicine Inc

Geschlossen

BrancheGesundheitswesen

2.73 -2.85

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.7

Max

2.89

Schlüsselkennzahlen

By Trading Economics

Einkommen

23M

-53M

Verkäufe

-1.1M

3.6M

Gewinnspanne

-1,487.842

Angestellte

246

EBITDA

23M

-49M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+45.32% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

3. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

56M

240M

Vorheriger Eröffnungskurs

5.58

Vorheriger Schlusskurs

2.73

Nachrichtenstimmung

By Acuity

12%

88%

18 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Editas Medicine Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

17. Sept. 2025, 23:01 UTC

Akquisitionen, Fusionen, Übernahmen

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17. Sept. 2025, 22:48 UTC

Akquisitionen, Fusionen, Übernahmen

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17. Sept. 2025, 21:59 UTC

Ergebnisse

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17. Sept. 2025, 23:44 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

17. Sept. 2025, 23:39 UTC

Market Talk

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17. Sept. 2025, 22:20 UTC

Akquisitionen, Fusionen, Übernahmen

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17. Sept. 2025, 22:20 UTC

Akquisitionen, Fusionen, Übernahmen

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17. Sept. 2025, 22:20 UTC

Akquisitionen, Fusionen, Übernahmen

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17. Sept. 2025, 22:19 UTC

Akquisitionen, Fusionen, Übernahmen

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17. Sept. 2025, 22:18 UTC

Akquisitionen, Fusionen, Übernahmen

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17. Sept. 2025, 21:00 UTC

Ergebnisse

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17. Sept. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

17. Sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. Sept. 2025, 19:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. Sept. 2025, 19:59 UTC

Market Talk

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17. Sept. 2025, 19:07 UTC

Market Talk

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17. Sept. 2025, 18:43 UTC

Market Talk

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17. Sept. 2025, 18:38 UTC

Market Talk

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17. Sept. 2025, 18:20 UTC

Market Talk

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17. Sept. 2025, 18:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. Sept. 2025, 18:18 UTC

Market Talk

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17. Sept. 2025, 18:14 UTC

Market Talk

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17. Sept. 2025, 17:59 UTC

Market Talk

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17. Sept. 2025, 17:15 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17. Sept. 2025, 17:06 UTC

Akquisitionen, Fusionen, Übernahmen

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17. Sept. 2025, 16:51 UTC

Ergebnisse

Correct: Exor 1H Net Loss -EUR624M

17. Sept. 2025, 16:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. Sept. 2025, 16:34 UTC

Market Talk

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17. Sept. 2025, 16:25 UTC

Ergebnisse

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17. Sept. 2025, 16:23 UTC

Ergebnisse

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Peer-Vergleich

Kursveränderung

Editas Medicine Inc Prognose

Kursziel

By TipRanks

45.32% Vorteil

12-Monats-Prognose

Durchschnitt 3.88 USD  45.32%

Hoch 6 USD

Tief 1 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Editas Medicine Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

12 ratings

5

Buy

5

Halten

2

Sell

Technischer Score

By Trading Central

1.33 / 1.54Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Neutral Evidence

Langfristig

No Evidence

Stimmung

By Acuity

18 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
help-icon Live chat